Opinion Discussion | Technical advantages and breakthroughs of Cellgene™ Care hemostatic materials
Chitosan is a powdery matrix with a linear molecular structure, lacking physical strength and wet stability.
In extreme battlefield rescue situations, ensuring the survival of the wounded is the top priority, without considering some hemostatic conditions such as cytotoxic reactions, immunogenicity, and allergic reactions required by clinical medicine.
To make chitosan hemostatic materials have qualified physical tensile strength and wet stability, toxic crosslinking agents are often needed. Non-toxic crosslinking agents, however, fail to meet the requirements of physical strength and wet stability.
Cellgene™ Care
To address the above issues, the use of cross-linking agents to cross-link chitosan and prepare hemostatic agents has been developed. However, to obtain a new type of chitosan material that is wet-stable, rapidly hemostatic, non-toxic, non-antigenic, does not increase the risk of infection, does not affect tissue healing, and is moderately priced in the market, the cross-linking agent becomes crucial. However, the currently publicly available chitosan hemostatic material preparation techniques, it is still unable to fully meet the needs of the clinical military and police for various reasons.
In view of this, after long-term efforts, the research and development team has, through international pioneering and exclusive patented freeze-drying cross-linking preparation method, changed the original molecular structure of chitosan, making Cellgene™ Care arterial hemostatic sponge the world's first wet-stable new high-molecular-weight arterial hemostatic sponge, solving the scientific research problem that chitosan sponge encounters mechanical strength and toughness after blood wetting, and cannot support high-pressure and high-flow hemostasis. The product is a cross-linked network chitosan molecule, and a piece of hemostatic material is equivalent to a structurally complete and stable network macromolecule.
Using the internationally patented covalent cross-linking technology, the product is composed of cross-linked networked chitosan molecules, where each hemostatic material is equivalent to a structurally complete networked macromolecule.
When Cellgene™ Care Arterial Hemostatic Patch comes into contact with a wound, it rapidly absorbs moisture from the blood. Simultaneously, the positively charged surface attracts negatively charged red blood cells and platelets to quickly aggregate at the wound site, forming a blood clot to seal the wound. This process rapidly and effectively activates the body's clotting mechanism, achieving a highly efficient and rapid hemostatic effect. The hemostasis mechanism is not affected by inherent clotting disorders.
Cellgene™Care Arterial Hemostatic Patch
is a novel high molecular weight arterial hemostatic material prepared using an innovative freeze-drying cross-linking technology. It is suitable for hemostasis of arterial bleeding wounds, interventional puncture sites, and catheter incisions.
Cardiology: Coronary angiography + PCI, interventional treatment for arrhythmia, interventional treatment for congenital heart disease, balloon angioplasty, cardiac catheterization, and other arterial interventions mainly through the radial artery.
Neurology and Neurosurgery: Cerebral angiography, vascular stenting and stent placement, endovascular embolization therapy, tumor-feeding artery embolization, and other arterial interventions mainly through the femoral artery.
Vascular Surgery: Endovascular stent placement, arterial thrombolysis, stent placement, embolization therapy, and other arterial interventions mainly through the femoral artery.
Interventional Radiology: CAG+PCT, lower limb angiography, lower limb thrombolysis intervention, balloon angioplasty, and other arterial interventions mainly through the femoral artery.
Oncology: Chemoembolization, chemotherapy infusion, selective arterial infusion chemotherapy, hepatic artery infusion/chemoembolization, and other arterial interventions mainly through the femoral artery.
Respiratory Medicine: Bronchial artery embolization, bronchial artery infusion chemotherapy, precise pulmonary artery thrombectomy, pulmonary artery angiography, and other arterial interventions mainly through the femoral artery.
1. The international pioneering freeze-drying cross-linking technology makes the product the only sponge in the country that can still be compressed after freeze-drying, with a clotting rate of over 90% after freeze-drying.
2. The mesh structure ensures product performance stability while possessing strong liquid absorption, absorbing over 30 times its weight in liquid.
3. The unique hemostasis mechanism involves a material surface with positive charges adsorbing red blood cells and platelets with negative charges, allowing the material to absorb liquid without adsorbing red blood cells.
4. The unique cross-linking agent provides the product with excellent physical tensile strength and wet stability, ensuring it does not break or dissolve when encountering body fluids or blood, meeting clinical arterial hemostasis requirements.
1. Reduce postoperative hemostasis time - decrease compression time, and improve operating room utilization.
2. Reduce postoperative immobilization time - lower the incidence of postoperative complications.
3. Reduce bandaging pressure - decrease nursing workload, alleviate patient discomfort, and enhance patient compliance.
4. Biological hemostatic materials - no drug infiltration, safer hemostasis; simple to use, higher cost-effectiveness.
Wechat｜Cellgene Care
LinkedIn｜Guangzhou Cellgene Biotechnology Co., LTD
